Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMO | O15229 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6476817 | 0.89 | MAPK14 (0.63) | POLBMAPTNPC1MAPK14SMN1; SMN2 | |
| SCHEMBL7799017 | 0.86 | MAPK14 (0.57) | POLBMAPTNPC1LMNAMAPK14 | |
| SCHEMBL30633564 | 0.80 | LMNA (0.54) | MAPTLMNAKMOHDAC1EPHX2 | |
| SCHEMBL20535115 | 0.80 | LMNA (0.54) | MAPTLMNAKMOHDAC1EPHX2 | |
| SCHEMBL6533294 | 0.79 | MAPK14 (0.63) | POLBMAPTNPC1MAPK14SMN1; SMN2 | |
| SCHEMBL6487599 | 0.77 | MAPK14 (0.61) | POLBMAPTNPC1MAPK14SMN1; SMN2 | |
| SCHEMBL12764351 | 0.77 | MAPT (0.62) | MAPTNPC1LMNAMAPK14HTT | |
| SCHEMBL6782804 | 0.77 | MAPK14 (0.73) | MAPTNPC1MAPK14HTTSMN1; SMN2 | |
| SCHEMBL7780464 | 0.76 | MAPK14 (0.65) | POLBMAPTMAPK14HTTSMN1; SMN2 | |
| SCHEMBL17478653 | 0.76 | KMO (0.59) | MAPTLMNAMAPK14HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212068-A1 | Benzamide derivatives for the treatment of diseases mediated by cytokines | ASTRAZENECA AB | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212068-A1 | Benzamide derivatives for the treatment of diseases mediated by cytokines | IL2, IL6, IL6ST | POLB 2378/4885MAPT 4386/4885NPC1 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.